RedHill Biopharma Releases Positive Data For Its Opaganib In Covid-19 Treatment

RedHill Biopharma Ltd. (RDHL) Monday said Opaganib, the company's antiviral drug candidate for the treatment of Covid-19, showed strong inhibition against South African and Brazilian variants in preclinical study.

Partnered with the University of Louisville Center for Predictive Medicine, opaganib was studied in a 3D tissue model of human bronchial epithelial cells to evaluate the in vitro efficacy of opaganib in inhibiting the Beta, South African and Gamma, Brazilian SARS-CoV-2 variants.

Opaganib exerts its antiviral effect by selectively inhibiting sphingosine kinase-2 (SK2), a key enzyme produced in human cells that can be recruited by the virus to support its replication.

RedHill Biopharma said opaganib's Phase 2/3 study in hospitalized patients with Covid-19 is fully enrolled and is expected to be completed in the coming weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT